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Abstract
Assessment of outcome in preclinical studies of vascular cognitive impairment (VCI) is heterogenous. Through an ARUK
Scottish Network supported questionnaire and workshop (mostly UK-based researchers), we aimed to determine
underlying variability and what could be implemented to overcome identified challenges. Twelve UK VCI research
centres were identified and invited to complete a questionnaire and attend a one-day workshop. Questionnaire
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responses demonstrated agreement that outcome assessments in VCI preclinical research vary by group and even those
common across groups, may be performed differently. From the workshop, six themes were discussed: issues with
preclinical models, reasons for choosing functional assessments, issues in interpretation of functional assessments,
describing and reporting functional outcome assessments, sharing resources and expertise, and standardization of
outcomes. Eight consensus points emerged demonstrating broadly that the chosen assessment should reflect the deficit
being measured, and therefore that one assessment does not suit all models; guidance/standardisation on recording VCI
outcome reporting is needed and that uniformity would be aided by a platform to share expertise, material, protocols
and procedures thus reducing heterogeneity and so increasing potential for collaboration, comparison and replication.
As a result of the workshop, UK wide consensus statements were agreed and future priorities for preclinical research
identified.
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Introduction
Dementia is a clinical and research priority condition,1
yet despite our best efforts we still have few proven
treatments for the disease.2,3 In vascular-related
dementias, the therapeutic options are especially limit-
ed.4 Recent years have seen concerted efforts to try and
progress the dementia research agenda and improve the
dementia drug discovery pipeline.5 As in many disease
areas, with stroke being the most relevant example, a
rate limiting step in translational dementia research has
been inconsistent or inefficient study outcomes
measurements.6
Reviews of the literature suggest that heterogeneity
in outcome assessment is a particular issue across all
dementia studies.7 Our objectives were to describe how
outcomes are assessed in pre-clinical vascular cognition
studies and to explore expert opinions on the optimal
approaches to testing. We describe the UK perspective,
through a focussed review of the literature, convening a
one-day workshop, complemented by questionnaire
data from those centres with active pre-clinical vascular
dementia research programs. In this report, we provide
context by describing the issues and potential solutions
to outcome assessment in other disease areas, notably
stroke. The findings of a literature review and the ques-
tionnaire and opinions from the workshop are then
analysed and summarised into a set of consensus state-
ments and priority directions for future research.
Vascular cognitive impairment research
Vascular cognitive impairment (VCI) is a term that
encompasses a spectrum of cognitive syndromes.8
The common feature is that the predominant
underlying pathology is of vascular origin. VCI
includes all forms of vascular dementia, cerebral amy-
loid angiopathy and also milder cognitive phenotypes
that do not meet the dementia criteria. Vascular disease
is generally said to be the second most common cause
of dementia after Alzheimer’s disease (AD).8 However,
there is increasing evidence that dementia in older age
is driven by more than one process and a vascular com-
ponent mixed with AD or other pathologies is
common.9 Thus, within the VCI remit there is a spec-
trum of both cognitive syndromes and underlying path-
ological states. The two do not necessarily map neatly
on to each other. Regardless of how VCI is categorised,
it represents a major and increasing cause of disability.
Despite the importance of VCI, compared to other
dementias such as AD, vascular causes of cognitive
decline are relatively under-researched. The landscape
is evolving and clinical, research and policy interest in
VCI is increasing. The use of multi-centre cohorts,10
‘big data’ and novel approaches to trials11 are all wel-
come developments but there remains an important
role for pre-clinical research,10 not least because at pre-
sent we have no proven and internationally licensed
treatment options for VCI.
The traditional process of drug discovery and devel-
opment has had only limited success in VCI and
dementia in general. Many potential therapeutic
agents have shown promise in pre-clinical studies and
early human phase II studies; however, these were
shown to have no beneficial effect when tested in defin-
itive phase III randomised controlled trials (RCTs).12
Recent neutral results across a portfolio of putative
AD treatments provide further evidence of the difficul-
ty in the bench to bedside translation.13
One conclusion, which parts of the pharmaceutical
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industry are considering, is that this whole approach is
misconceived. Before reaching such a conclusion, how-
ever, it should be asked whether there are key aspects
that currently hamper translation that could be
improved. Choice and translatability of outcome meas-
ures are one possible area. Certainly, for the research
community, the message seems to be that the status
quo is not working and that all aspects of the pipeline
should be reconsidered. Choice of outcome assessment
and the methods used to perform these assessments is
an important aspect of study methodology and there
may be potential to improve practice. Moving forward,
a bedside to bench approach that better models the
clinical condition is likely to uncover mechanisms
that can be targeted pharmacologically or remedially
for improved translation.
Learning from stroke research
The themes described in our discussion of VCI
research, namely: a substantial clinical problem with
limited pharmacological treatments, multiple positive
preclinical treatments and frequently disappointing
phase III results, were all true of stroke research in
the 1990s and early 2000s. Reflecting on the develop-
ments in contemporary stroke research can offer some
guidance for how we approach VCI research. A series
of high profile neutral results for neuro-protectant
agents was a driver for the stroke research community
to critically reflect on their approach to drug develop-
ment.14 Various working groups were convened, that
incorporated stakeholders from all aspects of the trans-
lational pathway including industry and regulatory
representatives. Documents and guidance, such as the
materials produced by the various Stroke Treatment
Academic Industry Roundtable (STAIR) meetings
and the Collaborative Approach to Meta-Analysis
and Review of Animal Data from Experimental
Studies (CAMARADES) group, have helped increase
efficiency and rigor in many aspects of the translational
approach.15–17 Many of the recommendations of
STAIR and CAMARADES have been adopted by fun-
ders, journal editors and regulatory agencies. It is dif-
ficult to quantify the success of these programs and we
should be cautious in ascribing changes in stroke
research success to these initiatives. However, it is
encouraging to see the growth in positive trial results
from new interventional, pharmaceutical and device-
based interventions in stroke.18–20
A key consideration of STAIR was to improve
methods and reporting of outcomes and trial end-
points. It was recognised that stroke trialists were
using a variety of different methods to quantify treat-
ment effects with no consensus on optimal measures or
approaches.21 This heterogeneity in assessment is
problematic as it complicates any attempt to compare
results or pool data for meta-analyses. Heterogeneity in
outcome assessment is particularly apparent when cog-
nitive tests are used as outcomes in stroke studies.22,23
In fact, a recent review suggested that there were more
assessments than there were trials. In response, a set of
core outcomes measures for stroke trials were sug-
gested with preferred tests for describing stroke impair-
ments and activity limitations.24 The concept of core
outcomes for stroke trials has been adopted by many
specialist societies and by regulatory agencies.25,26 The
move towards a more standardised approach to out-
come assessment is not unique to stroke. In many other
disease areas, heterogeneity and inconsistency in out-
come assessment are noted. The Core Outcome
Measures in Effectiveness Trials (COMET) initiative
aims to create and apply core outcome sets.27
COMET guidance has created core outcome sets for
many disease areas, recognising that defining a pre-
ferred test should not restrict researchers from measur-
ing other study specific endpoints of their choice.28
A recurring theme from the work around stroke out-
comes was that a stroke trial should have some mea-
sure of functional recovery. For many stroke trials, the
modified Rankin Scale (mRS) was the primary out-
come of choice.29 Although widely used, mRS was
not designed for use as trial outcome measure and
there were certain problems in the psychometric prop-
erties of the scale, most notably around inter-observer
variation in the grade assigned.30 Having settled on a
preferred outcome measure, the stroke research com-
munity developed methods to standardise mRS, includ-
ing training,31 structured approaches to questioning,32
expert adjudication panels33 and novel methods for
analysis.34,35 In respect of measuring cognitive out-
comes in acute stroke trials, few did (e.g. see ENOS
Trial Investigators36) in spite of recommendations to
do so.22,23 The substantial progress made around out-
come assessment in clinical stroke research should
serve as an exemplar for developing assessment strate-
gies in other research fields. Stroke assessment and VCI
assessment are far from synonymous, but there is suf-
ficient commonality in the diseases, the models and the
research challenges for the VCI pre-clinical research to
explore the potential application of recent methods
used to raise standards in stroke research outcome
assessment.
Review of the literature
To inform and give context to this work, we systemat-
ically reviewed the literature on outcome assessment in
pre-clinical VCI research. This work was taken from a
larger body of work with a more general pre-clinical,
functional outcomes remit.37 To complement this
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search of electronic literature databases, a search of the
COMET and EQUATOR (Enhancing the Quality and
Transparency Of health Research) databases found no
existing work on core outcome sets for VCI, although
preferred outcomes for clinical VCI research are in
preparation. In addition, we consulted the consensus
working group with the Stroke Recovery Research
Round Table (SRRRII) proceedings of a consensus
working groups that is focusing on stroke-induced cog-
nitive impairment.38
We assessed outcomes used in selected, published
pre-clinical VCI studies over a decade’s worth of
research (2005–2015) with dates chosen to reflect a
period of growth in the VCI research space. This was
part of a larger project analysing preclinical stroke
research that has been published and full details of
methods and results are available in the parent publi-
cation.37 From this work, we extracted data specific to
VCI research.
Across a decade of research, we found that VCI was
less frequently studied than other aspects of stroke. In
those papers with a predominant VCI focus, there was
substantial heterogeneity in outcome assessment with
many tests used in two papers or more (Figure 1). In
addition to those listed, the following outcome assess-
ments were described in only one paper: adhesive
removal test, buried food retrieval (olfactory), circular
hole board (dry maze), elevated plus maze, inclined
plane test, limb placement test, nest construction test,
porsolt swim test, social interaction in novel environ-
ment. For the assessment that was used most often, the
Morris Water Maze (MWM), we found marked incon-
sistency in how the test was performed and reported.
We had hoped to categorise the tests according to the
cognitive domain being tested, but such data were
infrequently reported. These VCI findings mirror the
results of a systematic analysis of studies using AD
mouse models.39 In transgenic mouse studies, there
was heterogeneity in assessments employed, with the
MWM was being the most commonly used test, yet
marked variations in the conduct and analysis of the
MWM testing were noted. There was a clear sex bias
with 62% of studies using only male animals, 3% only
female, 16% both sexes and 19% did not specify sex
used.37 Whilst we acknowledge a clear bias towards
using males in preclinical research exists, we support
and encourage the need to undertake more research
using both sexes (males and females) given known sex
differences exist.
These data come with certain caveats, the search was
restricted to priority journals with a cerebrovascular
focus and so is not a comprehensive synthesis of VCI
research. We also recognise that VCI research, models
and outcomes continue to evolve and some of the
newer models of VCI, for example those that model
amyloid angiopathy, may be under-represented. Thus,
the focus and time frame may omit other VCI models
(e.g. hypoperfusion, small vessel disease relevant)
which are more representative of the milder end of
the VCI spectrum and for which arguably there has
been more extensive behavioural testing. Accepting
these limitations, our illustrative review offers some
useful insights into outcome assessment in pre-clinical
VCI work.
Methods
We collated opinions and practices around pre-clinical
VCI assessment in UK academic centres. With support
from Alzheimer’s Research UK Scottish Network, we
held a one-day workshop, complemented by a ques-
tionnaire of usual practice. The work had ethical
approval from University of Glasgow, MVLS ethical
committee (ref:200170103). This work is the first in a
planned series designed to raise standards in pre-
clinical VCI research.
Sampling frame
Our approach was purposive, using our own knowl-
edge of VCI research and also consulting with
Alzheimer’s Research UK and Dementia Platform’s
UK Vascular Experimental Medicine Group to identify
Figure 1. Outcome assessments used in across a decade of
published VCI pre-clinical research. Outcomes described across
VCI research published (n¼ 37 articles) in selected journals
2005–2015 in more than two articles.
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UK academic centres with an active VCI research lab-
oratory. From an initial approach, we asked respond-
ents to name other researchers working in this space to
allow for a snowball distribution. Our focus was on
neurocognitive and behavioural outcomes. These are
functional tests and do not include measures of pathol-
ogy, neuroimaging or biomarkers. To align with the
clinical research literature, we use the term ‘functional
assessment’ to describe these tests.
Questionnaire
We followed best practice in design, conduct and
reporting of our questionnaire study.40 Academic
centres that were involved in the workshop were first
sent a short questionnaire by the study Principal
Investigators (LW and TQ). The bespoke questionnaire
was designed and piloted in-house before dissemina-
tion. The questionnaire focussed on the functional out-
come assessments used in pre-clinical VCI research and
large vessel stroke models by the respondents.
Additional questions explored perceived heterogeneity
in choice and application of functional outcome assess-
ment measures. The questionnaire was sent electronical-
ly with an explanatory cover letter (or by post on
request) and up to two reminder messages were sent if
no response was received. No incentive was offered for
completion. It was stated that completion of the ques-
tionnaire implied consent to participate and a separate
consent form was not used. We aimed to include all
relevant centres and so we did not perform sample
size calculations. Questionnaires were collated, results
entered into a database and described in aggregate using
simple descriptive statistics. The questionnaire had
space for free text comments, where these were complet-
ed verbatim comments were added to the results of the
focus group discussion described below. Recognising
that more than one PI may work in a centre, we accept-
ed more than one response from each Institute but
asked that each team should submit only one question-
naire. The full questionnaire is available in the
Supplementary Materials (Figure S1).
Workshop
We convened a one-day workshop on June 11 2018 in
the Institute of Cardiovascular and Medical Sciences,
University of Glasgow, UK. We used the same distri-
bution list as the questionnaire. Primary invitation was
sent to senior researchers within a centre, who also
nominated early career researchers to participate
where appropriate. We used a focus group approach,
with a moderator facilitating a semi-structured discus-
sion with a small group, resulting in three groups with
eight participants, one facilitator and one scribe. The
facilitator was one of three senior researchers with an
interest in VCI (LW, TQ, CMcC), and the scribe was
an early career researcher who took notes during the
discussions.
The day began with an overview presentation that
included the results of the literature review (described
above) and preliminary results from the questionnaire.
Two 1-h discussions were then held, the first focussing
on assessments used in the participants’ laboratory and
the second focussing on the application of tests for VCI
and other relevant models. Topics covered during the
discussions were guided by the group with the facilitator
ensuring that the following themes were all addressed:
choice of tests, rationale for choice, application of tests,
core outcomes sets. Each group offered feedback on
their discussions with the others in the room and this
conversation was also recorded by the scribe.
Responses were recorded as free text and these data
were shared with one of the research team (TQ) who
collated the comments and categorised as common
themes emerged. This process was continued until all
free text comments were categorised. The resulting
summary was electronically shared with all participants
for comment or correction. The statements presented
represent a final consensus on the topic. We provide a
narrative summary of the discussion, but as per our
ethical approvals, we do not attribute responses to a
particular participant.
Results
Questionnaire about choice of VCI outcome
measures
We identified 12 centres in the UK with an active VCI
research portfolio. For the questionnaire, we received
replies from 23 researchers, with responses from 11/12
of the centres approached. The majority, 18/23 (78%)
of respondents, said they did not agree that research
groups used the same tests in VCI research. Similarly,
the majority of responses, 21/23 (91%), said that the
approaches used and scoring were not consistent.
Respondents were asked to list all outcome meas-
ures that they used in VCI studies (Question 2,
Supplementary Figure 1), which generated a list of 23
assessments, most of which were used by a single
respondent (Table 1). We used the test names as
returned by the respondents and did not try to catego-
rise these. It could be argued that some responses with
different names are essentially the same test. Without
knowing the detail of the test, we opted not to combine
similar responses and instead present the responses as
submitted. Respondents interpreted the ‘functional’
assessment rubric in different ways and some of the
tests reported would not classically be considered as
McFall et al. 5
neurobehavioral assessments. The most commonly
used test was Novel Object Recognition followed by
the MWM. The original intention was to group test
by cognitive domain assessed. This was not possible
as some of the tests mapped across to various domains.
This difficulty in categorising VCI outcome assess-
ments was a discussion point during our workshop.
Workshop discussion summaries
The workshop included 30 participants, representing 12
different UK centres. Participants were 14 senior
researchers (head of department, chair or principal
investigator of a research group) and 16 early career
researchers. The comments generated were collated
into six themes, each described below. In addition,
the group agreed on a set of consensus statements
around current practice in pre-clinical VCI functional
outcomes research and some priorities for future work
in this area. The themes, consensus statements and
research priorities were shared with all contributors
and other international experts. Revisions were collat-
ed centrally by the lead authors (LMW, TJQ), incor-
porated without attribution and revised materials were
shared with the group. Process continued until no more
changes were suggested.
Theme 1: Issues with pre-clinical VCI models. The models
most commonly used by the participants’ research
groups were vessel occlusion models (permanent or
transient), microembolic models, models using vascular
risk factors and genetic vasculopathy models. This is
not an exhaustive list of models used by the partici-
pants and many other models were all discussed.
Each group raised issues around the suitability of func-
tional assessment in some of the commonly used VCI
models. Many groups use murine models but there was
debate around how well these models can capture the
cognitive phenotypes similar to those seen in clinical
VCI.41 There may be little benefit in designing a test
strategy to capture issues such as dysexecutive prob-
lems or language impairments, if the animal being
tested does not have a basic level of ability in these
domains even in health. Some participants felt that
aspects of executive function could be assessed in
mice, using attentional control, working memory, rule
learning and reversal-based assessment. Some other
laboratories are developing models in other larger spe-
cies such as pig.42 The advantages to this approach
were recognised, but these had to be weighed against
the increased costs and ethical considerations of work-
ing with these animals. Whilst larger animals including
non-human primates show some advantages for assess-
ing cognitive impairments over rodents, there still
remains the issue of not being able to assess language
and speech.
Another aspect of VCI models that was discussed
was the role of lesion specific modelling versus
models that create a more diffuse brain insult. It was
agreed that these different models require different
approaches to functional assessment – domain specific
testing may be relevant to models with precise lesioning
(e.g. focal endothelin-1 injection), while a more global
testing strategy may be useful in diffuse injury (e.g.
global hypoperfusion through bilateral carotid steno-
sis). Once again it was recognised that our limited
understanding of the pathology of human VCI preclud-
ed any definitive statement on the optimal pre-clinical
model that should be used. The agreement was that
whichever model is employed, the outcome assessments
must be relevant to the intended brain lesion. An alter-
native argument was made, rather than have the model
dictate the outcome assessments, we could consider
having the cognitive deficit of interest (i.e. the outcome)
inform the choice of model.
Theme 2: Reasons for choosing specific functional
assessments. All groups discussed the assessments that
they used in their laboratory and the reasons why one
test was preferred over another. A theme emerged that
the rationale for using a particular assessment was
often driven by practical considerations as well as sci-
ence. Groups described the time and training invest-
ment required to develop a functional assessment
protocol that is reproducible and robust for a
Table 1. Reported outcome measures used in UK VCI pre-clinical research centres.
Test No Test No Test No
Novel object recognition 5 Classical conditioning 1 Pole test 1
Morris water maze 4 Forced swimming task 1 Rotarod 1
Radial arm maze 3 Locomotor activity 1 Spatial recognition 1
Barnes maze 2 Modified Bederson 1 Sticky label 1
Neurovascular coupling 2 Nest building 1 T maze 1
Operant conditioning 2 Neuronal activity 1 Tail suspension table 1
Y maze 2 Open field 1 Touchscreen tests 1
Asymmetry 1 Paw placement 1 Visual acuity 1
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particular VCI model. Once a protocol is established,
this often meant that the included test was used in sub-
sequent experiments and grant applications. Groups
were resistant to changing established practice unless
clear benefit could be demonstrated. It was recognised
that the time and effort involved in becoming familiar
with testing were a barrier to new groups beginning
VCI research. All these points supported the calls for
greater sharing of resource and expertise.
Some of the testing paradigms favoured in the par-
ticipants’ centres had been modified from existing pro-
tocols used in non VCI-based models particularly AD
and stroke. Ultimately it was recognised that choice of
functional outcome assessment was not always driven
by neuropsychological considerations. The example of
the popular MWM was used, a test prevalent in VCI
research but that does not capture frontal lobe anom-
alies involving executive dysfunction, attention, proc-
essing speed, reaction time and object recognition.
Vascular cognitive impairments span multiple domains
and therefore no single measure is going to be appro-
priate to all VCI research. Tests need to be validated
for the domain of interest and if the function assessed
spans more than one neuroanatomical hub, then more
than one test may be required.
Some groups discussed the potential for new tech-
nologies, with translational relevance, to improve out-
come assessment.43 The example most widely
mentioned in resulting discussions was the use of
touchscreen-based test batteries designed for rodent
models but additionally relevant to the clinical setting.
Touchscreen-based assessments have the potential to
model human assessment tools and so could allow for
greater pre-clinical and clinical harmonisation of
assessment. Although groups were aware of digital
platforms that had been used for testing, only one of
the participants had expertise in using the technologies.
The group also had concerns over whether the cost,
and often lengthy protocol, justified adopting these
techniques in preference to more established assess-
ment strategies. There were also concerns over whether
grant funding bodies would view these technologies as
good value for money.
Theme 2: Consensus point.
• The functional outcomes measures that are best
suited to the study of VCI will often differ from
measures used in Alzheimer’s or other neurodegen-
erative pre-clinical research.
Theme 3: Issues in the interpretation of functional
assessments. There was a general recognition that all
of the commonly used functional assessments had
inherent limitations. It was felt that this did not inval-
idate the use of the tests but interpretation of the results
came with certain caveats. The models used to induce
VCI may not cause exclusive cognitive deficits. There is
the potential for performance on functional tests to be
confounded by other deficits for example a stroke
motor deficit could bias timed cognitive tasks such as
mazes.44 The same problem is seen when testing cogni-
tion in clinical stroke45 and only recently test batteries
have been developed that take account of non-cognitive
stroke deficits.46 In most centres, researchers screen ani-
mals before testing to ensure they are fit for the assess-
ment. Assessment varied according to the model and
the outcome being assessed and could include screening
for motor, visual or other sensory impairments. It was
felt that this could be formalised into a set of inclusion
and exclusion criteria that must be met before testing
and reported in results, a situation analogous to cogni-
tive testing in clinical research studies.
Another potential confounder, albeit more difficult
to quantify, is seen in the emotional and stress response
associated with the testing paradigm itself. Many cog-
nitive tests expose the animal to a novel situation or
involve fear, reward, food deprivation, etc. These fac-
tors may bias test performance, although it was felt
that this was less of an issue if a control group is
exposed to the same tests. Habituation of animals to
behavioural tasks needs also to be considered and
standardised. It was felt that experience and training
could reduce but not entirely remove these confound-
ing issues.
All of these issues lead to an inherent variability in
test performance and this in turn may necessitate large
numbers to demonstrate between group differences.
Statistical power analysis should be required to define
group sizes in VCI studies with functional outcomes to
avoid underpowered studies. This was an argument to
support standardisation of assessment and a move
towards larger, multi-centre collaborative projects.
The functional tests discussed were all designed to
assess issues at the level of impairment. In clinical
research, outcomes may assess more complex con-
structs such as disability (activity) or handicap (partic-
ipation).47 There was some discussion around whether
higher level functional issues could be captured in pre-
clinical models, for example through describing social
behaviours, or daily activity such as nesting. It was
recognised that animal housing and bedding would
need to be standardised if these behaviours were to
inform any outcome measure.
Some participants suggested that trying to make
sense of functional assessments in pre-clinical models
was, in fact, too ambitious. The question was raised as
to whether assessment of cognitive impairment, with
attendant need for equipment and experienced staff,
was even necessary. Instead, some form of quantifica-
tion of pathology, such as size of lesion (if appropriate
McFall et al. 7
to model) or change in a biomarker may be a sufficient
outcome for preclinical research. However, it was also
noted that in clinical research, relying solely on a sur-
rogate outcome has given misleading results and as a
result for stroke research, functional outcomes are now
preferred.
Cognition is a complex construct with differing
brain regions said to contribute to differing domains
of cognitive performance, for example the most recent
clinical definitions of neurocognitive disorder recognise
attention, learning and memory, language, visuospa-
tial, executive function and social cognition.48 For
some of the more popular functional tests, such as
the MWM, it was noted that it can be difficult to cat-
egorise exactly which cognitive domains are being
assessed by the test of interest. The MWM is usually
described in terms of learning and/or memory but
other cognitive domains (e.g. visuospatial) are also
involved in the execution of the task. Mapping the cog-
nitive domains being assessed to the available tests
could assist in choice of test strategies for future
research. There was a recognition that working with
behavioural neuroscientists and neuropsychologists
can aid the design, conduct and interpretation of cog-
nitive assessments, but that researchers with these skills
were limited in preclinical academic centres.
Theme 3: Consensus points.
• Choice of functional outcome in pre-clinical VCI
research should take account of anticipated cogni-
tive deficit, disease process being modelled and
potential confounders.
• Heterogeneity in choice, application and scoring of
outcomes in pre-clinical VCI research limits the
potential for comparison, collaboration and
replication.
• A standardised set of screening assessments (e.g.
motor, vision) could prevent confounding of cogni-
tive outcomes. These may be specific to the chosen
cognitive assessments.
Theme 4: Describing and reporting functional outcome
assessments. Whether or not assessments are standar-
dised to a consensus SOP, the testing strategy should
be described in sufficient detail to allow for replication
in another centre. The groups noted that reporting of
functional outcome assessment methods was variable
and there is potential to improve practice. The success
of initiatives such as the Animal Research Reporting of
In-vivo Experiments (ARRIVE) and other guidelines in
raising standards around reporting of pre-clinical
research was noted.49,50 However, the ARRIVE report-
ing checklist does not give specific guidance around
reporting of outcome assessment methods, specifically
how assessments were performed.51,52
The complexity of functional assessment and the
many potential factors that could influence test perfor-
mance were considered. As well as the potential varia-
tion in the actual test, factors specific to the animal
(time since lesion, age, sex), factors specific to the envi-
ronment (time of day, temperature, level of enrich-
ment) and factors specific to the researcher
(experience, contact time) could all modify test perfor-
mance. All these variables, and potentially many
others, should be recorded and it was agreed that
some guidance on the key factors that need to be
described in protocols and papers would be useful.
Not all animals complete a test as expected. For
example, one laboratory gave the example of mice
that often do not perform MWM appropriately and
consistently swim around the edge of the water rather
than engage in the task. These animals will not contrib-
ute any meaningful data to analyses and are excluded.
Such exclusions should be fully transparent and includ-
ed in any report, perhaps using a CONSORT flow dia-
gram style figure.
In the past, a barrier to the comprehensive descrip-
tions of different methods had been imposed by the
word limits imposed in journals. In present times,
with greater availability and use of online supplemen-
tary materials, this was felt no longer to be an issue.
Some delegates suggested that we could move towards
greater use of video to document process and applica-
tion of testing. It was noted that many journals now
mandate the use of reporting guidance (if available)
before a study is considered for publication.
Theme 4: Consensus point.
• Standardisation and guidance on the reporting of
outcomes in VCI research are needed.
Theme 5: Sharing resources and expertise. A theme that
dominated all the discussions was the need for greater
collaboration and co-design among centres. It was rec-
ognised that having different centres developing and
improving methods and protocols for the same assess-
ment,but working in isolation, was time and cost inef-
ficient. Many centres have developed their own
materials such as training manuals, standardised oper-
ating procedures (SOPS) and ‘troubleshooting’ guides
for outcome assessment but these are often only avail-
able for in-house use. Greater networking and collab-
oration between centres could facilitate information
sharing. The Home Office licence approvals required
for pre-clinical VCI work were recognised as another
example of a potentially valuable resource that is
required by all laboratories and that could be easily
shared between centres. In doing so this could lead to
greater standardisation across the UK in the conduct
of VCI studies, making the licensing procedure more
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efficient and streamlined, hopefully resulting in more
rapid approval of new licences and amendments.
Informal communication between laboratories, on its
own may not be sufficient to ensure visibility of the
various resources available. A free access to repository
for training materials, SOPS, etc. was a suggestion that
was met with approval from all delegates. Some mem-
bers noted that in clinical stroke, online training in
outcome assessment with certification had become
standard.31 Similar training could be developed for cer-
tain VCI outcomes. As well as the potential time and
cost savings of sharing resources, a single point of
access repository could also allow the research commu-
nity to map which outcomes had sufficient training
materials and guidance which outcomes needed such
materials to be developed.
Theme 5: Consensus point.
• The VCI research community needs a platform for
sharing SOPS, training, equipment and archived
tissue.
Theme 6: Standardisation of outcomes. Groups were
encouraged to discuss standardisation in choice and
application of functional outcomes. Opinions on the
utility of standardisation differed. Many recognised
the potential benefits but some group members also
voiced reservations about an overly prescriptive
approach. Many participants mentioned that training
in the application and interpretation of behavioural
testing is not uniform across centres. In particular,
there will be differences between dedicated behavioural
laboratories and more units with a more general
portfolio.
All groups discussed the potential of creating a core
set of preferred functional outcome assessments. While
this was broadly endorsed, there were some reserva-
tions. Outcomes should not be mandated and research-
ers should still have the flexibility to use tests of their
choosing. In many circumstances, particularly in early
phase experiments, the outcomes of interest need to be
chosen to align with the hypothesis being tested. The
work of COMET emphasises that autonomy in choice
of outcomes and use of a core outcomes set are not
mutually exclusive.27 The ideal scenario would involve
a battery of different tests, including certain core
assessments and also incorporating other tests specific
to the experiment.
There was general agreement amongst the delegates
that a ‘one size fits all’ approach is not suited to explor-
atory pre-clinical research. Functional outcomes of
interest in pre-clinical VCI research span a variety of
neurocognitive and behavioural domains. Rather than
a single preferred outcome, the group felt that a pref-
erable approach was to create a menu of preferred
tests, with tests suggested for all the various domains
of interest.
It was indicated that a move towards a standardised
test battery would be premature as we do not yet have
valid models that capture VCI and our understanding
of clinical vascular dementia syndromes is still evolv-
ing. The counter argument was that recommendations
around tests could change in-line with scientific prog-
ress and it would be wrong to delay moves towards
standardisation while important pre-clinical VCI
research was already in progress.
At a practical level, there was recognition that a
consensus approach to outcome assessment that was
described in a widely adopted standard operating pro-
cedure (SOP) would help with grant applications, sci-
entific protocols and applications towards approvals
required for animal-based research. Many groups dis-
cussed the increasing interest in multi-centre, pre-clin-
ical randomised controlled trials (pRCTs), with the
Multicentre Preclinical Animal Research Team
(Multi-PART) program of research cited as an exem-
plar of this approach.53 However, it was recognised
that this interest was not yet matched by a substantial
increase in pRCT activity. For true multi-centre work,
an agreed and standardised approach to outcome test-
ing would be essential, along with full support of grant
awarding bodies to fund such work. At the moment,
pRCT science is still at an early phase and it may be
difficult to mandate standardisation, when the
approach is still being refined.
Theme 6: Consensus points.
• A single mandated outcome assessment would not
be suitable for a complex construct such as VCI.
• A menu of preferred assessments for each cognitive
domain could improve standardisation.
Discussion
Using a multi-modal approach, we attempted to cap-
ture current practice and perceptions around functional
testing in pre-clinical VCI research. In this report, we
analyse and summarise the results of our literature
search, questionnaire survey and focus group. Our
review of selected, published VCI research suggested
substantial heterogeneity in the choice and application
of cognitive tests. Also, that the majority of VCI stud-
ies use male animals and fail to address the issue of sex
bias in pre-clinical research highlighting the need to
improve this important area. Researchers should be
encouraged to investigate both males and females in
VCI studies. Our questionnaires showed that inconsis-
tency in assessment is recognised as an issue by the
research community. To give these results context
and to explore the issues with greater granularity, we
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ran focus group discussions. Although there were dif-
fering opinions around certain aspects of testing, there
was substantial common ground and we were able to
agree on consensus statements and priorities for future
research (Textboxes 1 and 2).
To ensure that our process was robust, we engaged
with various stakeholder groups to ensure that we
achieved broad representation from the UK research
community. All of the centres that we approached par-
ticipated in either the questionnaire or focus groups.
We ensured we had representation both from senior
research leaders and from those earlier in their research
career who may have more direct, day-to-day experi-
ence with performing assessments. We sense checked
our results with international experts, who noted no
issues with generalisability of the main
recommendations, and used an iterative approach to
refining our consensus statements and research
priorities.
There are also limitations to our approach. It is pos-
sible that our sampling frame missed UK research
groups with an active VCI interest. We plan future col-
laborative methodological work that builds on this
project and any centres that wish to contribute in the
future can contact us. For this phase of the work, our
focus was the UK. The VCI research space is interna-
tional and in particular we recognise the work in this
area undertaken by National Institute of Health
and National Institute of Neurological Disorders and
Stroke raising similar issues within the AD and Related
Dementias Summit 2019.52 Our international groups
are also working towards consensus in VCI, such as
Stroke Recovery and Rehabilitation Roundtable who
are developing guidelines for improved translation of
cognitive assessments after stroke that span both pre-
clinical and clinical assessments.54 In the present work,
we limited the geographical scope of this first project as
we recognised that approvals and regulation of pre-
clinical research can vary internationally. However, in
many respects, the UK sample may not necessarily
differ from international experience as we use the
same variety of methods as are employed globally.
Before recommendations can be made around VCI
assessment, we would wish to repeat the exercise with
a broader, international group. The synthesis of the
focus group discussion was as objective as possible
but there is always an element of interpretation. To
ensure that what we report is an accurate representa-
tion, we shared all the data with participants, incorpo-
rating feedback and suggested changes until no more
alterations were needed.
Our discussion and recommendations were devel-
oped exclusively from the results of our literature
review, questionnaire and consensus meeting and,
accordingly, focused on outcome measures rather
than choice of model. From these sources, the predom-
inant models and approaches were rodent, for example
in our literature review only 2% of relevant VCI studies
used non-rodent models. This finding is in keeping with
other recent reviews of VCI models, where the non-
rodent models were all larger species (e.g. ruminants).42
The potential differences between mouse and rat VCI
models were not a major feature of our review or
others55 suggesting that these differences are perceived
as less important than other factors in the VCI com-
munity. General messages are applicable, for example
ensuring validity of assessments across animals and the
trade-off of cost/access versus similarity to the human
clinical condition. The use of drosophila and zebrafish
is gaining increasing traction in Alzheimer’s disease
dementia where exciting results are being produced
Textbox 2. Future research directions for pre-clinical
VCI functional outcomes
 Mapping available outcome measures to (clinical) cogni-
tive domains.
 Work with funders and journals to developing reporting
guidelines for outcomes.
 Need to explore role of new technologies.
 Explore developing multicentre approaches to VCI
research.
 Broaden this work to gain an international consensus.
Textbox 1. UK consensus on pre-clinical VCI func-
tional outcomes
 Choice of functional outcome should take account of
anticipated cognitive deficit, disease process of interest
and potential confounders.
 Heterogeneity in choice, application and scoring of
outcomes limits potential for comparison, collaboration
and replication.
 A standardised set of screening assessments (e.g. motor,
vision) could prevent confounding of cognitive out-
comes. These may be specific to the chosen cognitive
assessments.
 The VCI research community needs a platform for
sharing SOPS, training, equipment and archived tissue.
 The functional outcome measures that are best suited to
the study of VCI will often differ from measures used in
Alzheimer’s or other neurodegenerative pre-clinical
research.
 A single mandated outcome assessment is unlikely be
suitable for a complex construct such as VCI.
 A menu of preferred assessments for each cognitive
domain will improve standardisation.
 Standardisation and guidance on the reporting of out-
comes in VCI research are needed.
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with these species.56 Our results would suggest that
these models have less visibility in the VCI field.
Hence, while this paper focuses on outcome measures,
we appreciate the importance of having a valid model
and plan further work in this area.
The consensus conclusions and research priorities
that resulted from this project are presented in the
text boxes. We believe these will prove useful to
researchers but also to funders and journal editors.
We were encouraged by the willingness of the pre-
clinical VCI research community to work together on
this project and believe it could serve as an exemplar
for future methodological work. Other areas that could
benefit from similar consensus and guidance include
choice of VCI models and methods of analysis. In
other areas of stroke and dementia research, collabo-
ration, consensus and pooling of resources have driven
forward the research agenda.57 Hopefully, our experi-
ence in bringing together UK pre-clinical VCI research-
ers is the beginning of many future collaborative
activities.
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